

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	G1	of	G1	Application Number	09/525,797
-------	----	----	----	--------------------	------------

Complete if Known	
Application Number	09/525,797
Filing Date	03/15/2000
First Named Inventor	Athanasios A. Anagnostou
Group Art Unit	1642
Examiner Name	Susan Ungar
Attorney Docket Number	5218-39B

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Urushizaki, I. Domain of Chemotherapy. 10(6):1031-1037 (1994)	Partial
	2.	Anagnostou et al., "Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells", Proc. Natl. Acad. Sci. USA, 87(15):5978-5982 (1990)	
	3.	Fujioaka et al., "Effects of recombinant erythropoietin on kidney cancer cell growth and tumor angiogenesis", Autologous Blood Transfusion, 8(1):46-50 (1995)	Partial
	4.	Nagai, T., "Effects of recombinant erythropoietin on endothelin-1 production in cultured endothelial cells", J. of Japanese Soc. Of Nephrology, 36(3):194-200 (1994)	Partial
	5.	Japanese Office Action corresponding to Japanese Patent Application No. 513794/1998 mailed August 28, 2007.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	08/18/2008
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.